MoonLake Immunotherapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Recent price momentum is -22.5% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 6.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -60.5% | Better than 8% |
| Return on invested capital | -53.4% | Better than 5% |
Momentum D+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -29.8% | Better than 18% |
| 6-month return | -39.1% | Better than 13% |
| 12-month return (ex latest month) | -2.6% | Better than 30% |
| Distance below 52-week high | 52.5% | Better than 17% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 9.3x | Better than 93% |
| Debt to assets | 17.8% | Better than 59% |
| Interest coverage | -30.7x | Better than 9% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 87.5% | Better than 69% |
| Upside to average target | 221.3% | Better than 95% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 11.03
- Open
- 10.79
- Day range
- 10.73 - 11.31
- Avg price
- 11.08
- Volume
- 1.72M
- Turnover
- 19.10M
- Turnover ratei
- 3.17%
- Volume ratioi
- 1.29
- Amplitudei
- 5.26%
- 52-week rangei
- 9.46 - 23.29
Valuation
- P/Ei
- -3.14
- P/E (TTM)i
- -3.02
- P/Bi
- 2.47
- EPSi
- -3.53
- Book value / shi
- 4.48
- Net profit
- -300.43M
- Net assets
- 381.62M
Share structure
- Market cap
- 942.13M
- Float capi
- 601.79M
- Shares out
- 85.11M
- Float sharesi
- 54.36M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-10-20
52.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-25.01M net over the window
Short interest
- Shares short
- 5.47M
- % of floati
- 6.43%
- Days to coveri
- 2.85
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of MoonLake Immunotherapeutics (MLTX)?
MoonLake Immunotherapeutics last traded at 11.07. This page shows a periodic quote snapshot. Check the displayed quote time.
What is MoonLake Immunotherapeutics's market cap?
About 942.13M.
What is the P/E ratio of MoonLake Immunotherapeutics?
The trailing twelve-month P/E is -3.02. The Valuation tab shows it against the stock's own five-year range.
Does MoonLake Immunotherapeutics pay a dividend?
MoonLake Immunotherapeutics does not currently pay a regular dividend.
Is MoonLake Immunotherapeutics a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 35.57, which implies 221.3% upside from the current price. This is not investment advice.
What is MoonLake Immunotherapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates MoonLake Immunotherapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
MoonLake Immunotherapeutics discussion 0 comments